The Kindr GLP-1 Bridge Program. For patients whose coverage ended, not whose treatment should.

A coverage decision made in a state budget office should not decide your metabolic health. The Bridge Program is built for one situation: you were on a GLP-1, your coverage ended or was denied, and you need a clinician to tell you plainly what is still possible. It is a clinical review, not a discount code — and the first thing we look for is whether you already qualify for coverage under an indication nobody screened you for.

Who this is for

• You lost Medicaid GLP-1 coverage in 2026 because your state ended the benefit.
• Your prior authorization was denied or end-dated and you do not know why.
• You are in Michigan and no longer meet the BMI 40 threshold.
• You are in Rhode Island and your coverage ends October 1, 2026.
• Your commercial plan dropped weight-loss drugs at renewal.
• You stopped months ago, regained weight, and want a plan rather than a restart-and-hope.

What happens in the review

We start with your state. Coverage status, current Preferred Drug List criteria, and whether your plan is fee-for-service or managed care determine what is even worth pursuing — and that answer changes several times a year.

Then we look at you. Fasting insulin and HOMA-IR, HbA1c, a full lipid panel, hs-CRP, blood pressure, waist circumference, and a sleep-apnea screen. This is the step that changes outcomes: a woman told she was a weight-loss patient at 51 frequently turns out to have documentable insulin resistance progressing toward type 2 diabetes, or moderate sleep apnea, both of which carry a coverage pathway in every state.

If the record supports coverage, we help build the appeal around the exact criterion that was applied. If it does not, we say so directly and move to continuation options.

The continuity plan, either way

Why muscle protection is the non-negotiable part

Up to 25 to 40 percent of weight lost on a GLP-1 can be lean mass, and sarcopenia is already accelerating after 40. When treatment stops, fat returns faster than muscle does — which is how someone finishes a coverage interruption at the same weight with a worse body composition than they started. Protein at roughly 1.2 g/kg/day, resistance training two to three times weekly, creatine, and adequate vitamin D and calcium are part of every Bridge plan, on treatment or off it.

What this is not

• Not a guarantee of coverage, approval, or a prescription. Every treatment decision is made by a licensed clinician after clinical review.
• Not insurance, and not a substitute for your state Medicaid agency's determination.
• Not an emergency service. If you are having a medical emergency, call 911.
• Not a source for research chemicals or unlicensed suppliers. We work only with licensed pharmacies.

FAQ

Clinical sources

• KFF — Medicaid Coverage of and Spending on GLP-1s
• NEJM — Semaglutide 2.4 mg once weekly for weight management (STEP 1)
• NEJM — Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
• Journal of Cachexia, Sarcopenia and Muscle — Lean mass loss with GLP-1 therapy
• SWAN — Adiposity and metabolic changes across menopause
• NAMS / The Menopause Society — 2022 Hormone Therapy Position Statement
• Bone Health & Osteoporosis Foundation — Postmenopausal Bone Loss

Related guides

Explore more

• The complete Menopause Guide
• HRT guide cluster
• Free symptom checker
• Pricing

Information on this page is for educational purposes only and is not a substitute for individualized medical advice. Prescription medications require clinical evaluation and provider approval. Individual results vary. This is not an emergency service — if you are experiencing a medical emergency, call 911.